Approval of the first TCR-based cell therapy.
作者信息
Singh Nathan
机构信息
Division on Oncology, Section of Cellular Therapies, Washington University School of Medicine, St. Louis, MO, USA.
出版信息
Mol Ther. 2024 Oct 2;32(10):3195. doi: 10.1016/j.ymthe.2024.09.015. Epub 2024 Sep 20.
Abstract
摘要
相似文献
1
Approval of the first TCR-based cell therapy.首个基于T细胞受体的细胞疗法获批。
Mol Ther. 2024 Oct 2;32(10):3195. doi: 10.1016/j.ymthe.2024.09.015. Epub 2024 Sep 20.
2
Advances in CAR T-cell therapy for chronic lymphocytic leukemia.慢性淋巴细胞白血病的嵌合抗原受体T细胞疗法进展
Clin Adv Hematol Oncol. 2018 Feb;16(2):118-120.
3
T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.基于 T 细胞的免疫疗法：过继细胞转移和检查点抑制。
Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190.
4
Chimeric antigen receptor T cell therapy: 25years in the making.嵌合抗原受体T细胞疗法：历经25年研发而成。
Blood Rev. 2016 May;30(3):157-67. doi: 10.1016/j.blre.2015.10.003. Epub 2015 Nov 6.
5
FDA approves first TCR-engineered T cell therapy, for rare soft-tissue cancer.美国食品药品监督管理局批准首款经T细胞受体工程改造的T细胞疗法，用于治疗罕见软组织癌。
Nat Rev Drug Discov. 2024 Oct;23(10):731. doi: 10.1038/d41573-024-00134-z.
6
Managing allorejection in off-the-shelf CAR-engineered cell therapies.管理现成的嵌合抗原受体工程化细胞疗法中的同种异体排斥反应。
Mol Ther. 2024 Nov 26. doi: 10.1016/j.ymthe.2024.11.035.
7
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.工程策略增强 TCR 为基础的过继性 T 细胞治疗。
Cells. 2020 Jun 18;9(6):1485. doi: 10.3390/cells9061485.
8
Advances in T-cell Immunotherapies.T 细胞免疫疗法的进展。
Hematol Oncol Clin North Am. 2019 Oct;33(5):825-837. doi: 10.1016/j.hoc.2019.05.006. Epub 2019 Jul 4.
9
Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors.利用肿瘤微环境增强工程化淋巴细胞过继性 T 细胞疗法治疗实体瘤。
Semin Immunopathol. 2024 Jul 25;46(3-4):8. doi: 10.1007/s00281-024-01011-y.
10
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy.体外转录 mRNA 在过继性 T 细胞免疫治疗中的新作用。
Mol Ther. 2019 Apr 10;27(4):747-756. doi: 10.1016/j.ymthe.2019.01.018. Epub 2019 Feb 2.
引用本文的文献
1
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome.用于T细胞的CRISPR工具：靶向基因组、表观基因组和转录组。
Trends Cancer. 2025 Aug 28. doi: 10.1016/j.trecan.2025.08.001.
本文引用的文献
1
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.阿法替尼酶自体细胞输注治疗晚期滑膜肉瘤和黏液样圆形细胞脂肪肉瘤（SPEARHEAD-1）：一项国际性、开放性、2 期临床试验。
Lancet. 2024 Apr 13;403(10435):1460-1471. doi: 10.1016/S0140-6736(24)00319-2. Epub 2024 Mar 27.
2
Autologous T cell therapy for MAGE-A4 solid cancers in HLA-A*02 patients: a phase 1 trial.自体 T 细胞疗法治疗 HLA-A*02 患者的 MAGE-A4 实体瘤：一项 1 期临床试验。
Nat Med. 2023 Jan;29(1):104-114. doi: 10.1038/s41591-022-02128-z. Epub 2023 Jan 9.
Zotero 插件